In particular, therapies targeting the programmed cell death protein 1 (PD-1) receptor and programmed death-ligand 1 (PD-L1) pathway are providing treatment opportunities in a wide range of tumor types by modulating the immune system to control tumor growth [1, 2]. This evidence concerns the gene CD274 and neoplasm.